TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9846855
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin A (5000 IU/d until discharge)
Study: 7905256
Drug: Adjunctive imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive imipramine hydrochloride (mean, 233 +/- 72 mg/d)
Study: 2645914
Drug: Nicardipine 30
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 30 mg tid
Study: 2645914
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg tid
Study: 2645914
Drug: Nicardipine 30
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 30 mg tid and Propranolol 40 mg tid
Study: 1097295
Drug: Azathioprine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (1.5 mg per kg)
Study: 31027246
Drug: Caffeinated gel
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated gel (300 mg of caffeine)
Study: 28974184
Drug: Minimal supportive
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal supportive treatment/waitlist control
Study: 23473396
Drug: Fibrinolysis with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolysis with bolus tenecteplase (half dose for patients ≥75 years), clopidogrel, and enoxaparin before transport to a PCI-capable hospital.
Study: 21554679
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of salbutamol (15 μg kg ideal body weight‐1 hr‐1)
Study: 17852392
Drug: High-dose NovaSil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose NovaSil (3.0 g NS day(-1))
Study: 17852392
Drug: Low-dose NovaSil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose NovaSil (1.5 g NS day(-1))
Study: 17852392
Drug: Placebo-control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-control (0 g NS day(-1))
Study: 7814116
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART) technique
Study: 2735592
Drug: 20 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg normal saline infusion over 45 minutes
Study: 2735592
Drug: 15 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL/kg normal saline infusion over one hour (after first infusion)
Study: 2735592
Drug: 20 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg normal saline infusion over 45 minutes (Group B)
Study: 2735592
Drug: 15 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL/kg normal saline infusion over three hours (after first infusion)
Study: 31784345
Drug: Saury oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saury oil (12 g; 3.5 g of LCMUFA and 3.4 g of omega-3 FAs)
Study: 31784345
Drug: Control oil
Normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oil (identical capsules with a mixture of sardine and olive oil; 4.9 g of shorter-chain MUFA oleate and 3 g of omega-3 FAs)
Study: 27229178
Drug: Sitagliptin/metformin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin/metformin fixed-dose combination (Sita/Met)
Study: 10688506
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg misoprostol orally every 4 hours to a maximum of three doses
Study: 10688506
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin infusion according to the hospital protocol
Study: 9352869
Drug: Lymphoblastoid IFN-alpha
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoblastoid IFN-alpha (higher dosage and longer period)
Study: 31423687
Drug: Chemical cardioversion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical cardioversion with procainamide infusion
Study: 22692843
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneous every 6 months)
Study: 23597109
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day citalopram for 7 days
Study: 20626147
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) combined with small dose of clozapine (50 mg/d to 100‐150 mg/d, 3 times a week for 8 weeks)
Study: 20626147
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral administration of clozapine (50‐100 mg/d to 200‐500 mg/d, for 8 weeks)
Study: 20626147
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) combined with small dose of clozapine
Study: 19093056
Drug: Mandibular 2-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular 2-implant overdenture (IOD)
Study: 16224525
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and remifentanil (plasma concentration 4 microg/L)
Study: 16224525
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and remifentanil (plasma concentration 7 microg/L)
Study: 16224525
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion using propofol with Marsh parameters
Study: 10068928
Drug: UVA1 cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA1 cold light therapy
Study: 10068928
Drug: Combined UVA-UVB
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined UVA-UVB therapy
Study: 10068928
Drug: UVA1 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UVA1 therapy (4 weeks post-treatment)
Study: 28419855
Drug: Silymarin (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (700 mg, 3 times daily for 48 weeks)
Study: 26030948
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of ultrasound and TENS
Study: 26030948
Drug: Monotherapy (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (either ultrasound or TENS)
Study: 20857170
Drug: Lapatinib 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,500 mg PO daily
Study: 19500005
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with drugs
Study: 11158764
Drug: Gemifloxacin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin (320 mg)
Study: 15078000
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg)
Study: 11214127
Drug: Terbutaline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.5 mg as needed
Study: 25850968
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/day (monotherapy)
Study: 25850968
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/day + Metformin ≥1500 mg/day (add-on therapy)
Study: 16869994
Drug: Fermented gruel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented gruel with live L. plantarum 299v
Study: 12616127
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human erythropoietin (r‐HuEPO) 300 IU/kg body weight plus 100 mg iron intravenously
Study: 12616127
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication and iron
Study: 9499605
Drug: Pentavalent antimony
Normalized name: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent antimony compound (sodium stibogluconate)
Study: 3793333
Drug: diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem (60 mg)
Study: 20959578
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d)
Study: 10473054
Drug: hCRH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCRH (1 microg/kg/h in saline) infusion
Study: 29741923
Drug: PRP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP treatment (n = 27)
Study: 29231359
Drug: Acupoint pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint pressure therapy applied at uterine orifice dilation of 2 to 3 cm, 5 to 6 cm, 7 to 8 cm, and 9 to 10 cm.
Study: 29231359
Drug: Acupoint pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint pressure therapy (observation group)
Study: 29231359
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no acupoint pressure therapy)
Study: 17262713
Drug: Hyperosmolar gel
Normalized name: HYPEROSMOTIC LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperosmolar gel
Study: 17262713
Drug: Iso-osmolar gel
Normalized name: iso-sulfan blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso-osmolar gel
Study: 15274066
Drug: Subcutaneous interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interferon-alpha (9 MU daily) - Arm A
Study: 15274066
Drug: Subcutaneous interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interferon-alpha (9 MU daily) plus oral 13-cis retinoic acid (1 mg/kg) - Arm B
Study: 25799356
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow (NHF) system at 30 L/minute
Study: 25799356
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow (NHF) system at 50 L/minute
Study: 25799356
Drug: Oxygen at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen at 5 L/minute through a nasal cannula (NC5 group)
Study: 24195548
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg) plus abacavir-lamivudine once daily (DTG-ABC-3TC group)
Study: 24195548
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with efavirenz-tenofovir disoproxil fumarate-emtricitabine once daily (EFV-TDF-FTC group)
Study: 19682096
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment under a comprehensive dental programme
Study: 9869105
Drug: High-dose Epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Epirubicin (EPI) 120 mg/m2 plus Cisplatin (CP) 60 mg/m2
Study: 9869105
Drug: Vinorelbine (VNR)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (VNR) 25 mg/m2 plus Cisplatin (CP) 60 mg/m2
Study: 7657856
Drug: Cimetidine (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1600 mg per day)
Study: 7657856
Drug: Famotidine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (80 mg per day)
Study: 2621066
Drug: St. Thomas'
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. Thomas' hospital solution (potassium concentration 20 mmol/l) - group A
Study: 2621066
Drug: Ringer's injection
Normalized name: COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's injection (potassium concentration 4 mmol/l) - group B
Study: 4834097
Drug: Induction dose
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction dose of methohexitone 1.0 mg/kg
Study: 4834097
Drug: Induction dose
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction dose of methohexitone 1.4 mg/kg
Study: 28667230
Drug: Combination povidone
Normalized name: Povidone
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination povidone iodine and sodium fluoride dental varnish
Study: 19154844
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual activities and medications)
Study: 7594512
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose TNFR:Fc (10 mg/m2 i.v.)
Study: 7594512
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose TNFR:Fc (60 mg/m2 i.v.)
Study: 7594512
Drug: TNFR:Fc (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFR:Fc (both doses)
Study: 7033351
Drug: Sucralfate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (500 mg tablets, two tablets after meals and at bedtime)
Study: 7033351
Drug: Placebo (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablets after meals and at bedtime)
Study: 28803925
Drug: Swedish screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish screening protocol (2-year interval, PSA cut-off 3.0 ng/ml)
Study: 28803925
Drug: Lower PSA
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower PSA threshold in Finland (PSA cut-off <4.0 ng/ml)
Study: 28803925
Drug: Finnish screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finnish screening protocol (4-year interval, PSA cut-off 4.0 ng/ml)
Study: 29048238
Drug: Vitamin B12-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12-containing ointment (M-treatment)
Study: 29048238
Drug: Glycerol-petrolatum-based emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol-petrolatum-based emollient cream (C-treatment)
Study: 24226805
Drug: Ultrasound-assisted catheter-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-assisted catheter-directed thrombolysis (USAT) with 10 to 20 mg recombinant tissue plasminogen activator over 15 hours
Study: 24226805
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin alone (heparin group)
Study: 8291919
Drug: CPT-11 (irinotecan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (irinotecan) regimen A (100 mg/m2 weekly)
Study: 8291919
Drug: CPT-11 (irinotecan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (irinotecan) regimen C (200 mg/m2 every 3-4 weeks)
Study: 28591084
Drug: Local ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local ketamine 1 mg/kg instilled in the wound
Study: 28591084
Drug: Intramuscular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketamine 1 mg/kg
Study: 28591084
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mL normal saline instilled in the wound)
Study: 25394438
Drug: Sodium (Na)
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium (Na) bicarbonate infusion
Study: 20952003
Drug: 300 U
Normalized name: lactase 3300 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 U botulinum toxin-A intradetrusor injections excluding the trigone (detrusor arm)
Study: 20952003
Drug: 200 U
Normalized name: lipase 1200 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 U intradetrusor plus 100 U intratrigonal injections (combined arm)
Study: 11299091
Drug: Soybean protein
Normalized name: Soybean protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean protein intake (upper quartile: 8.7-35.2 g/day)
Study: 8203790
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (group D, n = 60)
Study: 8203790
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (group D)
Study: 3441747
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) administration of 2 micrograms
Study: 3441747
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) administration of 20 micrograms
Study: 3441747
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of 2 micrograms
Study: 3441747
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) and Intramuscular (i.m.) routes
Study: 29504671
Drug: HFNC 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC 6 L/minute
Study: 24985962
Drug: Enzalutamide and
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide and abiraterone in combination with standard-of-care
Study: 23615395
Drug: Theobromine (0.0011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine (0.0011 mol/l)
Study: 23615395
Drug: NaF toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF toothpaste slurry (0.0789 mol/l F)
Study: 19818785
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of immunosuppressive therapy (azathioprine) and 3 infusions of infliximab
Study: 19027269
Drug: Combination antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antipsychotic treatment
Study: 15705990
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (no ICS treatment)
Study: 10372700
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA; 5 mg/day)
Study: 10372700
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus MPA (0.625 mg/day conjugated equine estrogen and 5 mg/day MPA)
Study: 1801057
Drug: Conventional low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional low protein diet (0.6 g/kg/day protein, 800 mg phosphate; n = 33)
Study: 1801057
Drug: Low phosphate
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low phosphate diet (providing approximately 1000 mg phosphate plus an orally administered phosphate binder, minimum protein intake 0.8 g/kg/day; n = 30)
Study: 1801057
Drug: Control (minimum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (minimum protein intake 0.8 g/kg/day, no phosphate restriction; n = 32)
Study: 6859212
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (no. 1 pink tint)
Study: 6859212
Drug: Monofocal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monofocal treatment
Study: 6859212
Drug: Bifocal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifocal treatment
Study: 30904839
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a week programme (n=20)
Study: 28166914
Drug: Anti-tubercular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tubercular therapy (ATT) for 6 months
Study: 28166914
Drug: No anti-tubercular
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-tubercular therapy (no ATT)
Study: 27016906
Drug: Conservative Treatment
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative Treatment (CT), n = 42
Study: 27016906
Drug: Surgical Treatment
Normalized name: SURGICAL AIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical Treatment (ST), n = 42
Study: 27016906
Drug: Conservative Treatment
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative Treatment (CT), n = 41 (after follow-up)
Study: 27016906
Drug: Surgical Treatment
Normalized name: SURGICAL AIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical Treatment (ST), n = 40 (after follow-up)
Study: 11772148
Drug: Indapamide sustained-release
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide sustained-release (SR) 1.5 mg/day
Study: 3365665
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (8 mg/kg)
Study: 3365665
Drug: Low-dose metoclopramide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metoclopramide (0.8 mg/kg)
Study: 21960669
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir (600 mg)
Study: 21960669
Drug: Oral oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oseltamivir (75 mg)
Study: 21960669
Drug: Oral rimantadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rimantadine (100 mg)
Study: 21960669
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of peramivir with oseltamivir or rimantadine
Study: 19046761
Drug: 5-grass-pollen sublingual
Normalized name: Timothy grass pollen extract Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-grass-pollen sublingual immunotherapy tablets (300 IR)
Study: 9651560
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pravastatin
Study: 8582132
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) infusion at 24 mU kg‐1 min‐1
Study: 8582132
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) infusion at 12 mU kg‐1 min‐1
Study: 8582132
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) infusion at 6 mU kg‐1 min‐1